Regulatory and Reimbursement

Inaugural vaccine value chain conference talks about Team Australia

For the first time, key decision-makers and thought leaders from government, industry, academia, NGOs, and representatives from the immunisation community converged in a 2 day conference in Sydney hosted by Biointelect, highlighting the transformative potential of collaborative innovation.

Recognising service in health regulation

In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.

At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.

Family biz succeeds in vaccine approval & distribution

It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.

In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.

Nuclear medicine funding a win for men with prostate cancer

Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.

In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.

Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.

Entering The New Health Frontier

A new parliamentary report ‘The New Frontier: Delivering better health for all Australians’ is recommending significant reforms to the health care system to ensure Australians have better and faster access to the wave of new medicines and technologies.

The bipartisan report makes 31 recommendations to reform Australia’s system for the regulation and reimbursement with the hope that patients will receive faster access to the latest medicines and technologies.

Scroll to top